Analogues of neurohypophyseal hormones, oxytocin and arginine vasopressin, conformationally restricted in the N-terminal part of the molecule

Journal of Medicinal Chemistry

Volumn 49, Issue 6, 2006, Pages 2016-2021

  Kowalczyk, Wioleta ^a   Prahl, Adam ^a   Derdowska, Izabela ^a   Sobolewski, Dariusz ^a   Olejnik, Jadwiga ^b   Zabrocki, Janusz ^b   Borovicková, Lenka ^c   Slaninová, Jiřina ^c   Lammek, Bernard ^a  

^a UNIVERSITY OF GDA SK   (Poland)

^b LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

^c INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYMETHYLCYSTEINE; ARGIPRESSIN DERIVATIVE; ARGIPRESSIN[1 (3 MERCAPTOCYCLOHEXANEACETIC ACID) 4 VALINE]; ARGIPRESSIN[1 (3 MERCAPTOPROPIONIC ACID) 4 VALINE]; ARGIPRESSIN[1 MERCAPTOCYCLOHEXANEACETIC ACID]; ARGIPRESSIN[3 MERCAPTOPROPIONIC ACID]; ARGIPRESSIN[4 VALINE]; NEUROHYPOPHYSIS HORMONE; OXYTOCIN; OXYTOCIN[1 MERCAPTOCYCLOHEXANEACETIC ACID]; OXYTOCIN[3 MERCAPTOPROPIONIC ACID]; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANTIDIURESIS; ARTICLE; DRUG ACTIVITY; HORMONE ACTION; NEUROHYPOPHYSIS; PROTEIN CONFORMATION; STEREOCHEMISTRY;

3-MERCAPTOPROPIONIC ACID; ANIMALS; ANTIDIURETIC AGENTS; ARGININE VASOPRESSIN; DIPEPTIDES; FEMALE; MALE; MOLECULAR CONFORMATION; OXYTOCIN; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; UTERINE CONTRACTION; VASOCONSTRICTOR AGENTS;

EID: 33645381492     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm058038f     Document Type: Article

References (37)

1. Jard, S.; Barberis, C.; Audigier, S.; Tribollet, E. Neurohypophyseal hormone receptor systems in brain periphery. Prog. Brain Res. 1987, 72, 173-187.
2. Jard, S. Mechanisms of action of vasopressin antagonists. Kidney Int. 1988, 34, 38-42.
3. Manning, M.; Sawyer, W. H. Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin. J. Receptor Res. 1993, 13, 195-214.
4. Laszlo, F. A.; Laszlo, F., Jr.; De Wied, D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol. Rev. 1991, 43, 73-108.
5. Melin, P. Oxytocin antagonists in preterm labour and delivery. Bailliere's Clin. Obstet. Gynaecol. 1993, 7, 577-600.
6. Manning, M.; Cheng, L. L.; Klis, W. A.; Stoev, S.; Przybylski, J.; Bankowski, K.; Sawyer, W. H.; Barberis, C.; Chan, W. Y. Advances in the Design of Selective Antagonists, Potential Tocolytics, and Radioiodinated Ligands for Oxytocin Receptors; Ivell, R., Russel, J., Eds.; Plenum Press: New York, 1995; pp 559-583.
7. Lebl, M.; Jošt, K.; Brtník, F. Tables of Analogs in Handbook of Neurohypophyseal Hormone Analogs; Jošt, K., Lebl, M., Brtník, F., Eds.; CRC Press Inc.: Boca Raton, FL, 1987; Vol. II, Part 2, pp 127-267.
8. Liao, S.; Shenderovich, M. D.; Zhigang, Z.; Maletinska, L.; Slaninová, J.; Hruby, V. J. Substitution of the side-chain-constrained amino beta methyl-2,6-dimethyl-4-methoxytyrosine in position 2 of a bicyclic oxytocin analogue provides unique insights into the bioactive topography of oxytocin antagonists. J. Am. Chem. Soc. 1998, 120, 7393-7394.
9. Manning, M.; Bańkowski, K.; Sawyer, W. H. Selective agonists and antagonists of vasopressin. In Vasopressin; Gash, D. M., Boer, G. J., Eds.; Plenum Press: New York, 1987; pp 335-368.
10. Sobocińska, M.; Łempicka, E.; Konieczna, E.; Derdowska, I.; Lammek, B.; Melhem, S.; Kozik, W.; Janecka, J.; Janecki, M.; Trzeciak, H. I. Analogues of arginine vasopressin modified in position 2 or 3 with naphthylalanine: selective antagonists of oxytocin invitro. J. Pharm. Pharmacol. 2000, 52, 1105-1112.
11. Prochazka, Z.; Slaninová, J. The 1- and 2-naphthylalanine analogues of oxytocin and vasopressin. Collect. Czech. Chem. Commun. 1995, 60, 2170-2177.
12. Lammek, B.; Czaja, M.; Derdowska, I.; Rekowski, P.; Trzeciak, H. I.; Sikora, P.; Szkróbka, W.; Stojko, R.; Kupryszewski, G. Influence of L-naphthylalanine in position 3 of AVP and its analogues on their pharmacological properties. J. Pept. Res. 1997, 49, 261-268.
13. Toniolo C. Conformationally restricted peptides through short-range cyclizations. Int. J. Pept. Protein Res. 1990, 35, 287-300.
14. Czaplewski C.; Lammek B.; Ciarkowski J. Conformational constraints emerging in the N,N′-ethylene- and N,N′-propylene-bridged dipeptide units. Pol. J. Chem. 1994, 68, 2589-2598.
15. Vituox B.; Aubry A.; Cung M. T.; Marraud M. N-methyl peptides: VII. Conformational perurbations induced by N-methylation of model dipeptides. Int. J. Pept. Protein Res. 1986, 27, 617-632.
16. Lammek, B.; Czaja, M.; Derdowska, I.; Łempicka, E.; Sikora, P.; Szkróbka, W.; Trzeciak, H. I. Biologically active analogues of arginine vasopressin containing conformationally restricted dipeptide fragments. J. Pept. Res. 1998, 51, 149-154.
17. Łempicka, E.; Derdowska, I.; Jastrzȩbska, B.; Kuncarova, P.; Slaninová, J.; Lammek, B. Analogs of oxytocin conformationally restricted in the N-terminal part of the molecule. J Pept. Res. 2001, 57, 162-167.
18. Jastrzȩbska, B.; Derdowska, I.; Kowalczyk, W.; Machová, A.; Slaninová, J.; Lammek, B. Influence of 1-aminocyclohexane-1-carboxylic acid in position 2 or 3 of AVP and its analogues on their pharmacological properties. J. Pept. Res. 2003, 62, 70-71.
19. Kowalczyk, W.; Prahl, A.; Derdowska, I.; Dawidowska, O.; Slaninová, J.; Lammek, B. Highly potent 1-aminocyclohexane-1-carboxylic acid substituted V2 agonists of arginine vasopressin. J. Med. Chem. 2004, 47, 6020-6024.
20. Kowalczyk, W.; Prahl, A.; Dawidowska, O.; Derdowska, I.; Sobolewski, D.; Hartrodt, B.; Neubert, K.; Slaninová, J.; Lammek B. The influence of 1-aminocyclopentane-1-carboxylic acid at position 2 or 3 of AVP and its analogues on their pharmacological properties. J. Pept. Sci. 2005, in press.
21. Derdowska, I.; Prahl, A.; Kowalczyk, W.; Janecki, M.; Melhem, S.; Trzeciak, HI.; Lammek, B. Influence of enantiomers of 1-naphthylalanine in position 2 of VAVP and dVAVP on their pharmacological properties. Eur. J. Med. Chem. 2005, 40, 63-68.
22. Leplawy, M. T.; Olma, A. S-Benzyl-α-hydroxymethylcysteine: synthesis, resolution, absolute configuration. Pol. J. Chem. 1979, 53, 353-355.
23. Khalil, E. M.; Subasinghe, N. L.; Johnson, R. L. An efficient and high yield method for the N-tert-butyloxycarbonyl protection of sterically hindered amino acids. Tetrahedron Lett. 1996, 37, 3441-3444.
24. Hope, D. B.; Murti, V. V. S.; Du Vigneaud, V. A highly potent analogue of oxytocin, desamino-oxytocin. J. Biol. Chem. 1962, 237, 1563.
25. Rekowski, P.; Lammek, B. Synthesis of modified analogs of 1-(1-phenylmethylthiocyclohexane)-acetic acid. Pol. J. Chem. 1987, 61, 907-911.
26. Schnölzer, M.; Alewood, P.; Jones, A.; Alewood, D.; Kent, S. In situ neutralization in Boc-chemistry solid-phase peptide synthesis. Int. J. Pept. Prot. Res. 1992, 40, 180-193.
27. Manning, M. Synthesis by the Merrifield method of a protected nonapeptide amide with the amino acid sequence of oxytocin. J. Am. Chem. Soc. 1968, 90, 1348-1349.
28. Lammek, B.; Rekowski, P.; Kupryszewski, G.; Mellin, P.; Ragnarsson, U. Synthesis of arginine-vasopressin modified in position 1 and 2 as antagonists of the vasopressor response to the parent hormone. J. Med. Chem. 1988, 31, 603-606.
29. Kaiser, E.; Colescott, R. I.; Bossinger, C. D.; Cook, P. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 1970, 34, 595-598.
30. Christensen, T. C. A chloroanil color test for monitoring coupling completeness in solid-phase peptide synthesis. In Peptides - Structure and Biological Function; Gross, E., Meienhofer, J., Eds.; Pierce Chemical Company: Rockford, IL, 1979; p 385.
31. Stewart, J. M. Solid-Phase Peptide Synthesis; Pierce Chem. Corp.: Rockford, IL, 1984.
32. Holton, P. A modification of the method of Dale and Laidlaw for standardization of posterior pituitary extract. Br. J. Pharmacol. 1948, 3, 328-334.
33. Rudinger, J.; Krejči, I. Dose-response relations for some synthetic analogues of oxytocin, and the mode of action of oxytocin on the isolated uterus. Experientia 1962, 18, 585-588.
34. Dekanski, J. The quantitative assay of vasopressin. Br. J. Pharmacol. 1952, 7, 567-572.
35. Burn, H. J.; Finney, D. J.; Goodwin, L. G. Biological Standardization, 2nd ed.; Oxford University Press: London 1950; p 187.
36. Vávra, I.; Machová, A.; Krejčí, I. Antidiuretic action of 1-deamino-8-D-arginine vasopressin in unanesthetized rats. J. Pharmacol. Exp. Ther. 1974, 188, 241-247.
37. Slaninová, J. Fundamental Biological Evaluation. In Handbook of Neurohypophyseal Hormone Analogs; Jošt, K., Lebl, M., Brtník, F., Eds.; CRC Press Inc.: Boca Raton, FL, 1987; Vol. I, Part 2, pp 83-107.